CLAIMS

1. Pharmaceutical composition for topical use comprising a mixture, in the suitable polymer, of trichloroacetic acid, 2-hydroxybenzoic acid, (1α, 2β, 5α)-5-methyl-2-(1-methylethyl)cyclohexanol and, if desired, other pharmaceutically acceptable adjuvants and excipients.

2. Pharmaceutical composition according to claim 1, wherein the polymer is selected from the group consisting of polyethylene glycols, polyvinyl alcohol, polyoxyethylene alcohol.

3. Pharmaceutical composition according to claim 2, wherein the polyethylene glycols are selected form the group consisting of tetraethylene glycol, hexaethylene glycol.

4. Pharmaceutical composition according to claims 1-3, wherein the concentration of trichloroacetic acid is from about 20 % to about 45 % w/v.

5. Pharmaceutical composition according to claim 4 wherein the concentration of trichloroacetic acid is about 25 % w/v.

6. Pharmaceutical composition according to claims 1-2, wherein the concentration of 2-hydroxybenzoic acid is from about 10 % to about 30 % w/v.

7. Pharmaceutical composition according to claim 6, wherein the concentration of 2-hydroxybenzoic acid is about 20 % w/v.

8. Pharmaceutical composition according to claims 1-7 further comprising at least one corticosteroid.

9. Pharmaceutical composition according to claim 8, wherein the corticosteroid is selected from the group consisting of triamcinolone, betamethasone, methylprednisolone and dexamethasone.

10. Pharmaceutical composition according to claim 9, wherein triamcinolone is contained at a concentration from about 0,05 % to 20 %.

11. Pharmaceutical composition according to claim 10, wherein triamcinolone is contained at a concentration from about 0,01 % to 10 %.

12. Pharmaceutical composition according to claims 1-11, wherein adjuvants and excipients are ethanol and sodium chloride.

13. Pharmaceutical composition according to claims 1-12 for use in the treatment of cutaneous injuries.

14. Pharmaceutical composition according to claims 1-12 for use in the treatment of cutaneous injuries resulting from mechanical

traumas or surgical operations, burns, dermatitis both from animal sting and animal or poisonous plant contact.

15. Pharmaceutical composition according to claims 1-12 for use in the therapy and prevention of hypertrophic cicatrices and keloids.

16. Pharmaceutical composition according to claims 1-12 for use in aesthetic medicine.

17. Pharmaceutical composition according to claim 16 for use as exfoliating agent.

18. Pharmaceutical composition according to claims 1-17 in the form selected from the group consisting of ointment, gel, foam, liquid preparations, medicated plaster.

19. Process for the preparation of the pharmaceutical composition according to claims 1-18 comprising the following steps: a) prepare, in an anhydrous atmosphere, the distinct A and B mixtures, respectively, of (A) trichloroacetic acid at a concentration from about 40 % to about 90 % in the suitable polymer and (B) 2-hydroxybenzoic acid at a concentration from about 20 % to about 60 %, in the suitable polymer; b) mix, by adding small subsequent portions, same volumes of the two mixtures to obtain the A+B mixture; c) add a volume of a (1$\alpha$, 2$\beta$, 5$\alpha$)-5-methyl-2-(1-methylethyl)cyclohexanol saturated solution in anhydrous ethanol equal to 2 % of the volume of the A+B mixture; d) add sodium chloride in a such amount to obtain a final concentration of about 1,2 % w/v; e) keep the obtained composition in a bottle filled with anhydrous air at 30°C in reduced pressure conditions and leave at ambient temperature for about 24 hours.

20. Process according to claim 19, wherein the polymer is selected from the group consisting of polyethylene glycols, polyvinyl alcohol, polyoxyethylene alcohol.

21. Process according to claim 20, wherein the polyethylene glycols are selected form the group consisting of tetraethylene glycol, hexaethylene glycol.

22. Process according to claim 19-21, wherein to the mixture obtained in the step d) one or more corticosteroids is added.

23. Process according to claim 22, wherein the corticosteroids are selected from the group consisting of triamcinolone, betamethasone, methylprednisolone and dexamethasone.

24. Process according to claim 23, wherein triamcinolone is added in a such amount to obtain at a final concentration from about 0,05 % to about 20 %.

25. Process according to claim 24, wherein triamcinolone is added in a such amount to obtain at a final concentration from about 0,1 % to about 10 %.